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Transplant renal artery stenosis (TRAS) is a well-known cause of posttransplant hypertension accompanied by possible graft
dysfunctionandispotentiallycurablewhenisdiagnosedearly.ColourDopplerUltrasonography(CDU)isthescreeningprocedure
of choice in most studies whereas some centers employ Magnetic Resonance Angiography (MRA), if available. Although both
CDU and MRA can arouse suspicion of disease in less symptomatic cases, angiographic techniques are essential for conﬁrmation
ofTRAS.PercutaneousTransluminalAngioplasty(PTA)isagoodandwidespreadtherapeuticapproachforthetreatmentofTRAS
due to its acceptable complication rate and high technical success rate. The purpose of this paper is to assess the safety and eﬃcacy
of PTA in the treatment of TRAS, to compare the long-term outcomes between diﬀerent reports, and to examine the role of PTA
with stenting in inhibiting recurrence of the disease.
1.Introduction
Transplanted renal artery stenosis (TRAS) is the most com-
mon vascular complication of transplanted kidney, which
causes refractory hypertension and can result in allograft
dysfunctionwhichpresentswithincreaseofserumcreatinine
level. Transplanted renal artery stenosis (TRAS) usually
becomes apparent from 3 months to 2 years after transplan-
tation[1].Inrelationtoarterialanastomoticsite,thestenosis
canbe proximal because of recipients’ atherosclerotic arterial
disease, anastomotic due to surgical trauma in combination
with postoperative ﬁbrosis, and distal whose aetiology is not
well deﬁned, though mechanical and immunological factors
are implicated as possible causes [2]. Percutaneous translu-
minal angioplasty and stenting (PTAS) has as main purpose
the amelioration of graft function and blood hypertension.
2. Angioplasty andStenting in
TransplantRenal ArteryStenosis:
Technical andClinicalAspects
There is a wide range of incidence of TRAS varying from
1.8% to 25% according to the literature, indicating the
signiﬁcant role of surgical team as well as the importance
of the chosen screening procedure [3]. Clinical suspicion of
TRASisraisedbythepresentationofrefractoryhypertension
and the increase of serum urea and creatinine levels. Colour
Doppler Ultrasonography (CDU) is the most common
method used for the detection of renal artery stenosis,
because it is relatively inexpensive and harmless without
ionizing radiation, even though its diagnostic value depends
thoroughly on operator’s experience and skill. Although
both Magnetic Resonance Angiography (MRA) and Spiral
Computed Tomography Angiography (CTA) provide three-
dimensional image of the vascular tract, MRA is superior
to CTA with higher sensitivity and speciﬁcity, consisting
a viable technique for monitoring transplanted kidney’s
function; however the nephrotoxicity of contrast medium
used remains a limitation for imaging the transplanted
kidney with impaired function by tomographic methods.
MRA with the intravenous Gadolinium contrast medium
administration is the method of choice in cases of no
impaired renal function. However, in patients with severe
kidney failure it carries the risk of a possible nephrogenic
systemic ﬁbrosis as a complication. CTA is not usually
indicated, because of the iodine contrast nephrotoxicity in2 Journal of Transplantation
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Figure 1: (a) Anastomotic transplant renal artery stenosis. (b)
Postpercutaneous transluminal angioplasty and stenting image.
high doses. Yet, for conﬁrmation of TRAS selective percu-
taneoustransluminalangiography,whichneedslow-contrast
medium quantities, is still considered as the gold standard
[2–5].
Three diﬀerent treatment modalities are available for
patients with TRAS: (i) medical management is indicated if
the degree of stenosis is not considered hemodynamically or
clinically very signiﬁcant (<50%) and/or renal function has
not been deteriorated signiﬁcantly; (ii) surgical revascular-
ization is indicated for cases of unsuccessfulPTA or whenthe
stenosis is not accessible to PTA; (iii) PTA accompanied by
stent implantation (PTAS) when necessary is a less invasive
procedure and represents the preferred option even when
stenosis is in hilar or distal portion of the arterial renal bed.
The procedure of PTAS is well deﬁned and consists of the
following steps.
(1) Femoral artery approach is generally preferable
(brachial or axillary ones can rarely be used in case
of renal artery originating at close angle downward).
An arterial sheath of 4F up to 6F is placed in the iliac
artery, and then a guide wire is passed beyond the
area of the artery that is going to be treated.
(2) A preliminary angiographic study of the iliac arteries
in anteroposterior and oblique projections is the
initial, in order to localize the origin of renal artery
and to visualize the site and morphology of the lesion
(Figures 1(b), 2(b),a n d3(b)).
(3) Aftercrossingstenosiswithasoftguidewire,itisthen
replaced by a stiﬀer one to support balloon catheter.
Heparin in doses of 5000IU is also used to inhibit
thrombotic complications. Spasm of the arteries can
be reversed by administrating vasodilators.
(4) The balloon catheter is placed across the stenotic
area after angiographic control. The size of the
balloon is deﬁned by the diameter of the normal
adjacent area of the renal artery. Then the balloon
is inﬂated with a pressure comprised of about 5 to
10 atmospheres for about one minute, depending
on segment’s resistance. The above procedure can be
repeated two or three times, if it is necessary.
(5) The commonly used stents in PTA are balloon
expandable and are crimped onto a same diameter
balloon with this one used for previous angioplasty.
This assembly is passed over the guide wire across
the lesion, is inﬂated in correct position, and is then
withdrawn leaving the stent in place. Postprocedural
angiography is performed to ensure its position and
suitability (Figures 1(b), 2(b),a n d3(b)). Technical
success is considered when the residual stenosis does
not exceed 30% of the transplant renal artery normal
diameter.
(6) Hemostasis is achieved usually by manual compres-
sion, or, otherwise, a system of rapid hemostasis can
be used in special circumstances.
(7) Within 24–48 hours the clinical condition of the
patient is estimated considering blood pressure,
urine,andserumenzymesasparameters.Dropofthe
hypertension and serum urea and creatinine levels
indicate signs of clinical success.
3. SafetyandEfﬁcacy of Percutaneous
TransluminalAngioplastyandStenting in
TransplantRenal Artery Stenosis
Many reports in the literature address the role of PTA in
patients with TRAS based upon its acceptable complication
rate and its high technical and clinical success rates (reported
as65–100%)(Table 1)[4–17].Indeedthemajorityofsurveys
show few acute complications and achievement of prompt
correction of the stenosis. Pappas et al. [8]m a d ear e t r o s p e c -
tive analysis of 22 patients with TRAS, all cases conﬁrmed by
angiography. All patients were handled by PTA with stent-
ing immediately after the intra-arterial angiography. The
technical success rate—elimination of stenosis—was 100%,
no acute complications were veriﬁed, and amelioration of
arterial hypertension and improvement of graft function
were achieved within the ﬁrst 7 postoperative days. In a
follow-up period ranging from 3 to 104 months, two of 22
patients died from irrelevant causes with no graft functionJournal of Transplantation 3
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Figure 2: (a) Transplant renal artery stenosis. (b) Postpercutaneous transluminal angioplasty and stenting image.
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Figure 3: (a)Transplant renal arterystenosisand postbiopsyarteri-
ovenous ﬁstula. (b) Postpercutaneous transluminal angioplasty and
stenting and post-embolization image.
impairment, two experienced renal transplant failure (6
and 20 months after PTA), and the remaining 18 patients
had good graft function with decreased blood pressure and
decreased creatinine blood levels. Authors prefer PTA and
PTAS as initial treatment of TRAS underlining the safety and
eﬃcacy of these procedures and suggest that surgery should
be restricted to patients with failed PTA or with stenosis
inaccessible to PTA due to its high risk of complications.
In most recent reports a few major procedure-related
complications occur (range from 0% to 10%), in contrast
to surgery which is associated with a 15% graft loss rate
and 5% mortality rate, reﬂecting the gained experience and
suﬃcient equipment that have improved means of PTA
[6, 18, 19]. Only in a large and long-standing (within 24-
year time period) retrospective analysis by Peregrin et al.
[9] complications were observed in 25.5% (13/51) of proce-
dures. Speciﬁcally, three patients underwent kidney function
impairment due to contrast medium nephrotoxicity leading
to graft failure in one of them, while in the other two impair-
ment was reversible; groin hematoma and pseudoaneurysm
happened in four patients, all of them treated successfully
percutaneously; dissection of the dilated lesion occurred
in ﬁve patients, treated with stent implantation without
functional deterioration of graft; one patient experienced
peripheral branch occlusion without any clinical sequel.
Regarding long-term outcomes, the assumption of
investigation of the literature is promising. In several studies
a signiﬁcant decrease in serum creatinine as well as in blood
pressure is underlined, and in some cases there was also
decrease of the antihypertensive doses. In particular, in
a trial by Bertoni et al. [20] of nine patients with TRAS
undergone PTA, technical success was 100%, and arterial
hypertension was controlled in seven patients out of nine
and remarkably after one year from stenting seven patients
remained normotensive and medication-free. On the other
hand, PTA results may vary according to the duration of
follow-up period. A graft survival rate of 95% after one year
and 82% after two years has been reported [21]. Moreover,4 Journal of Transplantation
Table 1: Studies published over the last decade presenting transplant renal artery stenosis treated by percutaneous transluminal angioplasty
and stenting.
Study (year) Number of
patients
Technical
success (%)
Clinical
Success (%)∗
Follow-up
(mean; months)
Complications related
to the procedure (%)
Ghazanfar et al. (2011) [4] 44 100 86 60 —∗∗
Saratnahaei et al. (2010) [5] 9 100 77.7 17.3 —
Henning et al. (2009) [6] 13 92.3 Not
mentioned 33.15 —
Hagen et al. (2009) [7] 24 93 75 3 14
Pappas et al. (2008) [8] 22 100 91 29.5 —
Peregrin et al. (2008) [9] 55 88 65 36 25.5
Geddes et al. (2008) [10] 27 100 88.8 60 7.4
Valpreda et al. (2008) [11] 30 100 80 85.2 2.9
Polak et al. (2006) [12] 7 100 83.3 25.3 —
Audard et al. (2006) [13] 29 93.1 67.2 148 10.3
Salvadori et al. (2005) [14] 26 100 76.3 43.3 —
Voiculescu et al. (2005) [15] 31 90.3 75.5 45.2 12.9
Beecroft et al. (2004) [16] 17 100 94 27 10.5
Patel et al. (2001) [17] 17 94 82 26.9 —
∗Estimated as signiﬁcant clinical beneﬁt or good graft function during the whole follow-up period.
∗∗No procedure-related complication mentioned.
there is a variety of diﬀerent parameters used in diﬀerent
studies to determine the beneﬁcial eﬀect of PTA on graft
function that are not constantly reported so that comparison
between studies becomes obscure.
Another matter of interest is whether PTA can aﬀect
restoration of transplanted kidney function. In a relatively
recent study by Peregrin et al. [9], 6 out of 12 patients
who experienced graft failure or were in dialysis programme
days to weeks before PTA improved graft function for at
least 6 months so that these patients could remain dialysis-
free for some period of time. On the other hand, three
patients who underwent graft failure and unsuccessful PTA
started dialysis within days after PTA. In the same survey
transplanted patients were divided to subgroups based
on the clearance of creatinine (Ccr) and the comparison
between those with impaired graft function (range of Ccr
from 0.2 to 0.5/1.73m2/(mLs)) and those with Ccr above
0.5/1.73m2/(mLs) and revealed no signiﬁcant diﬀerence
in graft survival conﬁrming and supporting the idea that
successful PTA can reinforce graft function.
If PTA alone, the procedure carries higher risk of
restenosis with a recorded incidence from 10% to 33% of
cases over 6 or 8 months and from 16% to 62% of cases in
general [13]. Many recent reports highlight the crucial role
of PTA with stenting in limitation of recurrence, with success
rate between 90 to 100% [22]. Remarkably, as discussed in
a study by Salvadori et al. [14], the 5-year actuarial survival
rate was similar in patients with TRAS treated with PTA and
stenting (76.3%) versus patients who had also undergone
renal transplantation and had not developed TRAS (72.9%).
Based on these promising documents some authors
suggest stent implantation already at ﬁrst angioplastic proce-
dure. In addition, the use of radioactive stents or stents that
release antiproliferative agents to inhibit intimal hyperplasia
can decrease the incidence of recurrence further more.
4. Conclusion
In conclusion, PTA alone or in combination with stent
implantation is a well-established technique and is also
the initial interventional procedure of choice for high
grade TRAS, due to its lower invasiveness and less severe
complications, which overweigh the small possibility of
noneﬀectiveness. Surgical revascularization is indicated if
PTA cannot be done or if it is unsuccessful. Undoubtfully,
close collaboration between nephrologist, surgeon and inter-
ventional radiologist is required aiming the adoption of the
most suitable procedure for each patient.
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